Updated BEXMAB data in frontline HR-MDS shows complete remission rate substantially increased to 43%
“The continued maturation of the BEXMAB data demonstrates bexmarilimab’s profound impact as a disease-modifying agent,” said Dr. Petri Bono, Chief Medical Officer of Faron. “Seeing the CR rate strengthen over time to 43%, which complements the robust 50% cCR we have already reported, is very encouraging. It provides us with two compelling and clinically meaningful data sets for discussion with the FDA and gives us confidence in proposing a randomized registrational trial designed for accelerated approval with either CR or cCR as the primary endpoint.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data